Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.

Arthritis Rheumatol 2016 08;68(8):1914-21

Novartis Pharma AG, Basel, Switzerland.

Objective: To assess whether secukinumab treatment in patients with active psoriatic arthritis (PsA) is associated with sustained inhibition of radiographic progression.

Methods: In this phase III, double-blind, placebo-controlled study, 606 patients with PsA were randomized to receive intravenous (IV) secukinumab at a dose of 10 mg/kg (weeks 0, 2, 4) followed by subcutaneous secukinumab at a dose of 150 mg or 75 mg (the IV→150 mg and IV→75 mg groups, respectively) or placebo. Patients were stratified according to prior anti-tumor necrosis factor (anti-TNF) exposure (71% were anti-TNF naive). At week 16, placebo-treated patients who had at least a 20% reduction in the tender and swollen joint counts (responders) continued to receive placebo until week 24; nonresponders were re-randomized to receive secukinumab at a dose of 150 mg or 75 mg. The modified total Sharp/van der Heijde score (SHS) was determined at baseline, week 16 or 24, and week 52.

Results: In the overall population, radiographic progression was inhibited through 52 weeks; efficacy was demonstrated for both erosion and joint space narrowing scores and in patients who switched from placebo to secukinumab at week 24. Subgroup analyses showed that secukinumab reduced radiographic progression at week 24, regardless of previous anti-TNF treatment. Among anti-TNF-naive patients, the mean changes from baseline to week 24 in the modified total SHS were 0.05 in the pooled secukinumab group and 0.57 in the placebo group; among patients with an inadequate response or intolerance to anti-TNF treatment, the mean changes were 0.16 and 0.58, respectively. Anti-TNF-naive patients showed negligible progression through week 52. Inhibition of structural damage was observed through week 52 irrespective of concomitant methotrexate use. A high proportion of patients receiving secukinumab showed no progression (change in SHS of ≤ 0.5) from baseline to week 24 (82.3% of the IV→150 mg group and 92.3% of the IV→75 mg group) and from week 24 to week 52 (85.7% of the IV→150 mg group and 85.8% of the IV→75 mg group).

Conclusion: Secukinumab inhibited radiographic progression over 52 weeks of treatment in patients with active PsA.

Download full-text PDF

Source
http://eprints.whiterose.ac.uk/98522/14/Heijde_et_al-2016-Ar
Web Search
http://doi.wiley.com/10.1002/art.39685
Publisher Site
http://dx.doi.org/10.1002/art.39685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129532PMC
August 2016
54 Reads

Publication Analysis

Top Keywords

week
12
baseline week
12
radiographic progression
12
secukinumab dose
12
patients
10
secukinumab
9
psoriatic arthritis
8
treatment patients
8
anti-tnf-naive patients
8
anti-tnf treatment
8
dose 150
8
week week
8
progression week
8
active psoriatic
8
patients active
8
modified total
8
phase iii
8
iv→150 group
8
structural damage
8
sustained inhibition
8

References

(Supplied by CrossRef)
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
Gladman et al.
Ann Rheum Dis 2005
Psoriatic arthritis
Day et al.
J Am Acad Orthop Surg 2012
Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis
Menon et al.
Rheumatol 2014
Psoriatic arthritis imaging: a review of scoring methods
Heijde et al.
Ann Rheum Dis 2005

Similar Publications